In subgroup analyses, high PSMC4 expression particularly compromised prognoses in patients with early-stage lung adenocarcinoma (N0/N1 and pathological stages I-II), indicating its potential as an early adverse prognostic marker (Figures 4D–I). This evidence concerns the gene PSMC4 and lung adenocarcinoma.